ArticleFrontiers in cardiovascular medicine2025
Hepatocyte growth factor and B-type natriuretic peptide as independent predictors of mortality in HFpEF patients.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A liver-heart endocrine axis revealed by systems genetics and mediated by hepatocyte growth factor activator.medRxiv : the preprint server for health sciences · 2026Article
- Hepatocyte growth factor alleviates alcoholic cardiomyopathy through the Nrf2 pathway-a focus on iron metabolism.Journal of thoracic disease · 2025Article
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) is a common and heterogeneous syndrome with high mortality and morbidity. However, few studies have evaluated the relationship between biomarkers and subsequent outcomes in HFpEF patients. Objective: To assess the association between plasma hepatocyte growth factor (HGF) levels and all-cause mortality in HFpEF patients. Methods: This was a retrospective cohort study of 412 HFpEF patients who were hospitalized in the Department of Cardiology of the First Affiliated Hospital of Anhui Medical University from November 2020 to November 2021. The patients were divided into two groups according to the 24-month follow-up results: deceased (82 cases) and survivors (330 cases). The primary outcome was all-cause mortality. Multivariate logistic regression analysis was performed to identify the risk factors for all-cause mortality in HFpEF patients. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of relevant indicators for HFpEF mortality risk. Kaplan-Meier analysis was used to assess the risk of all-cause mortality in patients with increased relevant indicators. Results: Multivariate logistic regression analysis showed that HGF, B-type natriuretic peptide precursor (BNP), total protein (TP), estimated glomerular filtration rate (eGFR), and tetraiodothyronine (T4) were independent risk factors for all-cause mortality in HFpEF patients ( Conclusion: HGF and BNP are independent risk factors for all-cause mortality events in HFpEF patients during 24 months of follow-up, and the survival probability of HFpEF patients with low HGF and BNP concentrations is higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.